Valantine Hannah sold $280K of CDNA
Valantine Hannah sold 12,103 shares of CareDx, Inc. (CDNA) at $23.11 ($0.28M total) on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (shares, price, total value) and confirmation of a pre-arranged 10b5-1 plan; no additional company performance or guidance information is included.
Market read
Useful for monitoring insider activity, but the 10b5-1 structure reduces the likelihood of a strong fundamental repricing catalyst.
What to watch
Traders may over-weight insider sales; without accompanying changes in guidance, financing, or clinical/regulatory updates, the fundamental signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).
Ticker impact
CareDx director Valantine Hannah sold 12,103 shares in an open-market transaction at $23.1123 on a 10b5-1 plan, per Form 4.
Likely limited immediate price impact; any effect is more sentiment/flow-driven than fundamental.
The disclosure is a routine Form 4 insider sale with explicit 10b5-1 pre-arrangement, and no new operating/financial catalyst is provided.
Market effects
No sector-level read-across; this is company-specific insider transaction data only.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.
Key entities
- issuerCareDx, Inc.
US-listed company whose director insider sale is disclosed on Form 4.
- insiderValantine Hannah
Director reporting an open-market sale under a 10b5-1 plan.
